三生制药(01530)于2026年2月4日发布截至2026年1月31日的证券变动月报。报告显示，公司注册股本及已发行股份数量在报告期内均保持不变，未有新增发行、购回、注销或库藏股活动。
公司注册股本方面，普通股法定/注册股份数目维持50,000,000,000股，每股面值0.00001美元，法定/注册股本合共500,000美元，与上月无差异。已发行股份也维持在2,538,005,412股，未有任何库藏股份持有，说明平稳运行下无股份新增或回购注销事宜。
公司进一步确认，截至本月末已符合适用的公众持股量要求。根据公告信息，期内并无股份期权或股权激励计划的授出、行使、失效，也无可换股票据或其他协议安排导致的股份变动。
本次月报由公司秘书黎少娟签署。三生制药表示，将继续遵守香港联交所《上市规则》及相关法律法规的要求，确保公司信息披露的及时性和规范性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.